Arch Biopartners Begins Patient Dosing in Canada in Phase II Trial For LSALT Peptide

MT NewswiresNov 11 08:03 ET

Units for Debt Settlement

GlobeNewswireSep 26 08:46 ET

Arch Biopartners Receives Approval From Alberta Health Services to Proceed With Phase II Trial

MT NewswiresSep 11 07:08 ET

Arch Biopartners' Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins

GlobeNewswireAug 2 07:20 ET

Arch Biopartners Closes Non-Brokered Private Placement

GlobeNewswireJul 30 16:47 ET

Arch Biopartners Arranges Non-Brokered Private Placement

GlobeNewswireJul 29 16:52 ET